The Food and Drug Administration seeks comments by August 13, 2012, on draft and revised draft guidances for industry describing product-specific bioequivalence recommendations regarding the design of studies to support abbreviated new drug applications.  

The Food and Drug Administration (FDA) issues a guidance for small businesses titled “Toll-Free Number Labeling and Related Requirements for Over-the-Counter and Prescription Drugs Marketed with Approved Applications: Small Entity Compliance Guide.” FDA welcomes comments at any time.  

The Institute of Medicine’s Board on Health Sciences Policy announces a July 17-18, 2012, Washington, D.C., workshop titled “Assessing the Economics of Genomic Medicine.” The workshop’s goal is advancing “discussions around the clinical integration of genomic applications.”